Illumen Therapeutics is pursuing a moonshot in the treatment of aggressive cancers by increasing functional p53 with the development of PARN inhibitor drugs.

Illumen Therapeutics is pioneering the development of first-in-class PARN inhibitor drugs that boost functional p53, the 'Guardian of the Genome,' to treat aggressive cancers and improve survival. Dysregulation of p53, a key tumor suppressor, is the hallmark of nearly all cancers, making drugging p53 the Holy Grail of cancer drug development.